HSPA9 and breast carcinoma: In human breast cancer cells, treatment with the molecule embelin inhibits Grp75-p53 interaction, leading to the downregulation of Grp75 as long as metastatic signaling occurs, inhibiting mitochondrial fission and arresting growth (Nigam et al., 2015).